Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B.
Schwotzer R, et al. Among authors: pederiva s.
Hematol Oncol. 2019 Dec;37(5):595-600. doi: 10.1002/hon.2677. Epub 2019 Nov 6.
Hematol Oncol. 2019.
PMID: 31486522